
Welcome to Made Smarter Innovation | Digital Medicines Manufacturing research centre (DM²)
About DM²
The Digital Medicines Manufacturing Research Centre, known as DM² was a 3.5-year flagship programme operating from 2022-25, co-created and co-delivered with industry.
With a focus on enabling digital design, DM² has been delivering CMAC’s strategic priorities to improve digital maturity in medicines manufacturing and develop a workforce of the future that can flourish in these digitalised lab environments.

DM² Aims
DM² aims to advance medicines development, manufacture, quality control and supply through the creation of data-driven Industrial Digital Technologies (IDTs) including AI, robotics and digital twins.
Outputs
Crystallisation DataFactory
Achieving faster, more accurate, and insightful results with the Crystallisation DataFactory.
By developing a platform for rapid solvent screening, precise API habit indication, and early estimation of kinetic parameter, the Crystallisation DataFactory scrutinises data to ensure high-quality fair storage allowing for thorough interrogation and deeper understanding.
Tableting DataFactory
Setting the bar for a new era of rapid, efficient, and scalable tablet production.
Our Tableting DataFactory accelerates formulation and process development to under 24 hours with only a few grams of material.
The AI-driven robotic platform, combined with a predictive system of models, rapidly selects and optimises formulation and process conditions, ensuring they are ready for scale-up.
Capsule filling: Linking digital twins, data factory, and digital quality control
Our simulation models showcase how digital quality control can significantly enhance process consistency and product quality.
By simulating the movement and interaction of particles during the capsule-filling process, we can design a control strategy to define process parameters, material properties and the optimal operating range.